Achilles Therapeutics PLC ACHL.OQ, ACHL.O is expected to show no change in quarterly revenue when it reports results on November 11 (estimated) for the period ending January 1 0001
LSEG's mean analyst estimate for Achilles Therapeutics PLC is for a loss of 41 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Achilles Therapeutics PLC is $2.00, above its last closing price of $1.05.
This summary was machine generated November 8 at 15:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments